CRK-A NOVEL TARGET FOR CANCER THERAPY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Mar 30, 2012
filing date -
Mar 31, 2011
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
This disclosure identifies a novel apoptotic compensatory proliferation signaling complex (ASCS) involving ExoT's cellular target, Crk1. This disclosure demonstrates that in cells induced to undergo apoptosis, Crk1 forms globular complexes which associate with plasma membrane in the apoptotic cell and are released from the dying cell to its healthy neighbor, inducing it to proliferate. ExoT prevents the ACSC assembly while inducing apoptosis, indicating that apoptotic program cell death and compensatory proliferation are distinct and can be uncoupled from each other. Without being bound to any particular theory, it is believed that Crk1 functions as a scaffold for the ACSC assembly and that its ADP-ribosylation by ExoT interferes with this process while resulting in anoikis apoptotic cell death.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully